(Q35609056)

9 August 2017

1 reference

title

The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. (English)

1 reference

9 August 2017

main subject

anti-retroviral agent

0 references

visceral leishmaniasis

1 reference

López-Vélez R

1

1 reference

9 August 2017

publication date

1 October 2003

1 reference

Annals of Tropical Medicine and Parasitology

9 August 2017

published in

1 reference

9 August 2017

volume

97 Suppl 1

1 reference

9 August 2017

page(s)

143-147

1 reference

Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

Visceral leishmaniasis in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

Fever of uncertain origin in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

HIV-associated visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART)

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

Dynamics of serum cytokines in patients with visceral leishmaniasis and HIV-1 co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from subjects coinfected with human immunodeficiency virus and Leishmania infantum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

Prospective Evaluation and Follow-Up of European Patients with Visceral Leishmaniasis and HIV-1 Coinfection in the Era of Highly Active Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F000349803225002615

10.1179/000349803225002615

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference